Respira Therapeutics, Inc.

- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Respira Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05567367
- Locations
- 🇦🇺
Nucleus Network, Burnet Institute, Prahran, Victoria, Australia
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Respira Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05343637
- Locations
- 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇦🇺Royal Hobart Hospital, Hobart, Tasmania, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
- Conditions
- Pulmonary Arterial Hypertension
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Respira Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04266197
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States